Lead Product(s) : TT-01025
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : LG Chem
Deal Size : $350.0 million
Deal Type : Licensing Agreement
LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH
Details : Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.
Product Name : TT-01025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : TT-01025
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : LG Chem
Deal Size : $350.0 million
Deal Type : Licensing Agreement